vs
Amneal Pharmaceuticals, Inc.（AMRX）与Regions Financial Corporation（RF）财务数据对比。点击上方公司名可切换其他公司
Regions Financial Corporation的季度营收约是Amneal Pharmaceuticals, Inc.的1.6倍（$1.3B vs $814.3M），Regions Financial Corporation净利率更高（41.7% vs 4.3%，领先37.4%），Amneal Pharmaceuticals, Inc.同比增速更快（11.5% vs 4.1%），过去两年Amneal Pharmaceuticals, Inc.的营收复合增速更高（11.1% vs 4.0%）
Amneal Pharmaceuticals是一家美国上市制药企业，核心业务涵盖仿制药及专科药物的研发、生产与分销，总部位于新泽西州布里奇沃特，是美国规模最大的仿制药生产商之一。
Regions Financial Corporation是美国银行控股企业，总部位于阿拉巴马州伯明翰市。公司提供零售及商业银行、信托、股票经纪、抵押贷款等服务，旗下银行业务子公司Regions Bank在美国南部和中西部15个州运营约1300家营业网点和2000台自动柜员机，服务大量当地个人及企业客户。
AMRX vs RF — 直观对比
营收规模更大
RF
是对方的1.6倍
$814.3M
营收增速更快
AMRX
高出7.3%
4.1%
净利率更高
RF
高出37.4%
4.3%
两年增速更快
AMRX
近两年复合增速
4.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $814.3M | $1.3B |
| 净利润 | $35.1M | $534.0M |
| 毛利率 | 36.5% | — |
| 营业利润率 | 13.8% | 55.3% |
| 净利率 | 4.3% | 41.7% |
| 营收同比 | 11.5% | 4.1% |
| 净利润同比 | 212.9% | 0.0% |
| 每股收益（稀释后） | $0.10 | $0.59 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRXRF
| Q4 25 | $814.3M | $1.3B | ||
| Q3 25 | $784.5M | $1.3B | ||
| Q2 25 | $724.5M | $1.3B | ||
| Q1 25 | $695.4M | $1.2B | ||
| Q4 24 | $730.5M | $1.2B | ||
| Q3 24 | $702.5M | $1.2B | ||
| Q2 24 | $701.8M | $1.2B | ||
| Q1 24 | $659.2M | $1.2B |
净利润AMRXRF
| Q4 25 | $35.1M | $534.0M | ||
| Q3 25 | $2.4M | $569.0M | ||
| Q2 25 | $22.4M | $563.0M | ||
| Q1 25 | $12.2M | $490.0M | ||
| Q4 24 | $-31.1M | $534.0M | ||
| Q3 24 | $-156.0K | $490.0M | ||
| Q2 24 | $6.0M | $501.0M | ||
| Q1 24 | $-91.6M | $368.0M |
毛利率AMRXRF
| Q4 25 | 36.5% | — | ||
| Q3 25 | 34.9% | — | ||
| Q2 25 | 39.5% | — | ||
| Q1 25 | 36.8% | — | ||
| Q4 24 | 36.0% | — | ||
| Q3 24 | 38.4% | — | ||
| Q2 24 | 35.6% | — | ||
| Q1 24 | 36.1% | — |
营业利润率AMRXRF
| Q4 25 | 13.8% | 55.3% | ||
| Q3 25 | 9.0% | 56.3% | ||
| Q2 25 | 15.4% | 56.1% | ||
| Q1 25 | 14.4% | 52.0% | ||
| Q4 24 | 10.4% | 53.4% | ||
| Q3 24 | 12.6% | 49.9% | ||
| Q2 24 | 13.6% | 52.7% | ||
| Q1 24 | -1.6% | 39.2% |
净利率AMRXRF
| Q4 25 | 4.3% | 41.7% | ||
| Q3 25 | 0.3% | 45.3% | ||
| Q2 25 | 3.1% | 44.7% | ||
| Q1 25 | 1.8% | 41.0% | ||
| Q4 24 | -4.3% | 43.4% | ||
| Q3 24 | -0.0% | 40.2% | ||
| Q2 24 | 0.9% | 42.2% | ||
| Q1 24 | -13.9% | 31.1% |
每股收益（稀释后）AMRXRF
| Q4 25 | $0.10 | $0.59 | ||
| Q3 25 | $0.01 | $0.61 | ||
| Q2 25 | $0.07 | $0.59 | ||
| Q1 25 | $0.04 | $0.51 | ||
| Q4 24 | $-0.10 | $0.55 | ||
| Q3 24 | $0.00 | $0.49 | ||
| Q2 24 | $0.02 | $0.52 | ||
| Q1 24 | $-0.30 | $0.37 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.0M | — |
| 总债务越低越好 | $2.6B | $4.1B |
| 股东权益账面价值 | $-70.8M | $19.0B |
| 总资产 | $3.7B | $158.8B |
| 负债/权益比越低杠杆越低 | — | 0.22× |
8季度趋势，按日历期对齐
现金及短期投资AMRXRF
| Q4 25 | $282.0M | — | ||
| Q3 25 | $201.2M | — | ||
| Q2 25 | $71.5M | — | ||
| Q1 25 | $59.2M | — | ||
| Q4 24 | $110.6M | — | ||
| Q3 24 | $74.0M | — | ||
| Q2 24 | $43.8M | — | ||
| Q1 24 | $46.5M | — |
总债务AMRXRF
| Q4 25 | $2.6B | $4.1B | ||
| Q3 25 | $2.6B | $4.8B | ||
| Q2 25 | $2.2B | $5.3B | ||
| Q1 25 | $2.2B | $6.0B | ||
| Q4 24 | $2.4B | $6.0B | ||
| Q3 24 | $2.4B | $6.0B | ||
| Q2 24 | $2.4B | $5.1B | ||
| Q1 24 | $2.4B | $3.3B |
股东权益AMRXRF
| Q4 25 | $-70.8M | $19.0B | ||
| Q3 25 | $-109.5M | $19.0B | ||
| Q2 25 | $-112.1M | $18.7B | ||
| Q1 25 | $-131.7M | $18.5B | ||
| Q4 24 | $-109.3M | $17.9B | ||
| Q3 24 | $-93.4M | $18.7B | ||
| Q2 24 | $-57.5M | $17.2B | ||
| Q1 24 | $-63.7M | $17.0B |
总资产AMRXRF
| Q4 25 | $3.7B | $158.8B | ||
| Q3 25 | $3.6B | $159.9B | ||
| Q2 25 | $3.4B | $159.2B | ||
| Q1 25 | $3.4B | $159.8B | ||
| Q4 24 | $3.5B | $157.3B | ||
| Q3 24 | $3.5B | $157.4B | ||
| Q2 24 | $3.5B | $154.1B | ||
| Q1 24 | $3.5B | $154.9B |
负债/权益比AMRXRF
| Q4 25 | — | 0.22× | ||
| Q3 25 | — | 0.25× | ||
| Q2 25 | — | 0.28× | ||
| Q1 25 | — | 0.32× | ||
| Q4 24 | — | 0.34× | ||
| Q3 24 | — | 0.32× | ||
| Q2 24 | — | 0.30× | ||
| Q1 24 | — | 0.20× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $130.3M | $-319.0M |
| 自由现金流经营现金流 - 资本支出 | $108.5M | — |
| 自由现金流率自由现金流/营收 | 13.3% | — |
| 资本支出强度资本支出/营收 | 2.7% | — |
| 现金转化率经营现金流/净利润 | 3.72× | -0.60× |
| 过去12个月自由现金流最近4个季度 | $269.9M | — |
8季度趋势，按日历期对齐
经营现金流AMRXRF
| Q4 25 | $130.3M | $-319.0M | ||
| Q3 25 | $118.5M | $861.0M | ||
| Q2 25 | $83.8M | $573.0M | ||
| Q1 25 | $7.4M | $1.1B | ||
| Q4 24 | $118.1M | $-220.0M | ||
| Q3 24 | $141.8M | $1.3B | ||
| Q2 24 | $39.7M | $161.0M | ||
| Q1 24 | $-4.4M | $396.0M |
自由现金流AMRXRF
| Q4 25 | $108.5M | — | ||
| Q3 25 | $106.2M | — | ||
| Q2 25 | $61.0M | — | ||
| Q1 25 | $-5.8M | — | ||
| Q4 24 | $102.9M | — | ||
| Q3 24 | $124.8M | — | ||
| Q2 24 | $29.0M | — | ||
| Q1 24 | $-13.6M | — |
自由现金流率AMRXRF
| Q4 25 | 13.3% | — | ||
| Q3 25 | 13.5% | — | ||
| Q2 25 | 8.4% | — | ||
| Q1 25 | -0.8% | — | ||
| Q4 24 | 14.1% | — | ||
| Q3 24 | 17.8% | — | ||
| Q2 24 | 4.1% | — | ||
| Q1 24 | -2.1% | — |
资本支出强度AMRXRF
| Q4 25 | 2.7% | — | ||
| Q3 25 | 1.6% | — | ||
| Q2 25 | 3.2% | — | ||
| Q1 25 | 1.9% | — | ||
| Q4 24 | 2.1% | — | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | 1.5% | — | ||
| Q1 24 | 1.4% | — |
现金转化率AMRXRF
| Q4 25 | 3.72× | -0.60× | ||
| Q3 25 | 50.00× | 1.51× | ||
| Q2 25 | 3.74× | 1.02× | ||
| Q1 25 | 0.61× | 2.18× | ||
| Q4 24 | — | -0.41× | ||
| Q3 24 | — | 2.57× | ||
| Q2 24 | 6.62× | 0.32× | ||
| Q1 24 | — | 1.08× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRX
| Oral Solid | $188.7M | 23% |
| Distribution Service | $107.7M | 13% |
| Central Nervous System | $104.8M | 13% |
| Government Label | $86.8M | 11% |
| Other Dosage Forms | $68.2M | 8% |
| Transdermal | $56.1M | 7% |
| Hormonal Allergy | $47.6M | 6% |
| Ephinephrine Auto Injector | $39.1M | 5% |
| Injectable | $37.4M | 5% |
| Other | $33.6M | 4% |
| Biosimilar | $29.4M | 4% |
| Selling General And Administrative Expenses | $14.9M | 2% |
RF
| Consumer Bank | $747.0M | 58% |
| Corporate Bank | $487.0M | 38% |
| Wealth Management | $47.0M | 4% |
